Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
3 Dow Jones Stocks on Our Watchlist The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine.
These companies are leveraging their strengths to maintain leadership and reward investors.
Moderna Stock Looks Ripe for a Short Squeeze Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals MERCK & CO. (
NYSE:MRK ) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector.
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels.
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025 For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.
FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.
Top S&P500 movers in Tuesday's session Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.
Stay informed with the top movers within the S&P500 index on Tuesday. Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
These S&P500 stocks are gapping in today's session Stay tuned for the market movements in the S&P500 index on Tuesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN) Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.
Dow Jones Adds 1,000 Points, Breaks 200-Day Moving Average For First Time Since April 2 Tariff Shock The Dow surged 1,100 points after a U.S.-China trade truce, breaking above its 200-day average and fueling hopes of a market rebound — with caveats.
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries.
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
